MAPT and Alzheimer disease: In the revised criteria for diagnosis and staging of AD, published by AA workgroup, it is clearly stated that tau PET can discriminate between biological stages, categorized from A to D, whereas fluid biomarkers can only establish that an individual is in stage A or higher.